Reports Q2 revenue $1.1M, consensus $760,000. “We are on track with our business priorities as we focus on bringing BXCL501 to the greatest number of patients in need,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “We are pleased with the progress with our SERENITY and TRANQUILITY programs and our focused market-access strategy for IGALMI(TM). Our confidence in our lead neuroscience asset is underpinned by its broad therapeutic potential across multiple neuropsychiatric conditions and its growing intellectual property portfolio.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
- Bioxcel Therapeutics (BTAI) Q2 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
- BioXcel Therapeutics sees Q2 net revenues from sales of IGALMI of $1.1M